327 related articles for article (PubMed ID: 25866054)
21. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer.
Yang G; Zhou D; Dai Y; Li Y; Wu J; Liu Q; Deng X
Thorac Cancer; 2022 Nov; 13(21):2941-2950. PubMed ID: 36117149
[TBL] [Abstract][Full Text] [Related]
22. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.
Liu YY; Yang XY; Li Z; Liu ZL; Cheng D; Wang Y; Wen XJ; Hu JY; Liu J; Wang LM; Wang HJ
CNS Neurosci Ther; 2014 Jan; 20(1):76-85. PubMed ID: 24279586
[TBL] [Abstract][Full Text] [Related]
23. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.
Chen Y; Lian G; Liao C; Wang W; Zeng L; Qian C; Huang K; Shuai X
J Gastroenterol; 2013 Jul; 48(7):809-21. PubMed ID: 23179610
[TBL] [Abstract][Full Text] [Related]
24. Receptor-targeted gene delivery via folate-conjugated polyethylenimine.
Guo W; Lee RL
AAPS PharmSci; 1999; 1(4):E19. PubMed ID: 11741215
[TBL] [Abstract][Full Text] [Related]
25. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Guo J; O'Driscoll CM; Holmes JD; Rahme K
Int J Pharm; 2016 Jul; 509(1-2):16-27. PubMed ID: 27188645
[TBL] [Abstract][Full Text] [Related]
26. Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.
Zhang M; Zhang M; Wang J; Cai Q; Zhao R; Yu Y; Tai H; Zhang X; Xu C
Drug Deliv; 2018 Nov; 25(1):995-1003. PubMed ID: 29667478
[TBL] [Abstract][Full Text] [Related]
27. Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate.
Biswal BK; Debata NB; Verma RS
Mol Biol Rep; 2010 Jul; 37(6):2919-26. PubMed ID: 19816791
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
29. Polymer nanoassemblies with hydrophobic pendant groups in the core induce false positive siRNA transfection in luciferase reporter assays.
Rheiner S; Reichel D; Rychahou P; Izumi T; Yang HS; Bae Y
Int J Pharm; 2017 Aug; 528(1-2):536-546. PubMed ID: 28629980
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.
Kim N; Jiang D; Jacobi AM; Lennox KA; Rose SD; Behlke MA; Salem AK
Int J Pharm; 2012 May; 427(1):123-33. PubMed ID: 21864664
[TBL] [Abstract][Full Text] [Related]
31. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
32. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Li C; Han X
Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
[TBL] [Abstract][Full Text] [Related]
33. Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions.
Thiramanas R; Li M; Jiang S; Landfester K; Mailänder V
Cells; 2020 Sep; 9(9):. PubMed ID: 32906726
[TBL] [Abstract][Full Text] [Related]
34. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
36. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
37. Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Peng Y; Huang J; Xiao H; Wu T; Shuai X
Int J Nanomedicine; 2018; 13():3467-3480. PubMed ID: 29942129
[TBL] [Abstract][Full Text] [Related]
38. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
39. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro.
Wu Y; Wang W; Chen Y; Huang K; Shuai X; Chen Q; Li X; Lian G
Int J Nanomedicine; 2010 Mar; 5():129-36. PubMed ID: 20309399
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
